Tech Company Financing Transactions
Pinnacle Medicines Funding Round
Pinnacle Medicines, operating out of Doylestown, raised $89 million from Foresite Capital, LAV Fund and Hankang Capital.
Transaction Overview
Company Name
Announced On
3/26/2026
Transaction Type
Venture Equity
Amount
$89,000,000
Round
Series B
Investors
Foresite Capital (Lead Investor)
LAV Fund (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the advancement of its lead programs through clinical proof of concept, with an initial focus on immunology and cardiometabolic diseases, while further expanding its proprietary peptide discovery platform and research and development capabilities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Doylestown, PA Undisclosed
USA
Doylestown, PA Undisclosed
USA
Phone
Website
Email Address
Overview
At Pinnacle Medicines, our vision is to transform patients' lives through oral peptide therapeutics. Our team brings deep experience advancing first-in-class therapeutics from discovery through clinical development. Our pipeline is initially focused on developing oral peptides against targets validated by blockbuster biologic drugs. By creating oral alternatives to injectable therapies, we aim to broaden treatment access and improve the patient experience.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 3/25/2026: Adonis venture capital transaction
Next: 3/26/2026: Blossom Health venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








